1602575-00-7

Upstream product

• 1346529-71-2 4-(5-bromo-2,3-dihydro-benzofuran-2-yl)-piperidine 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 1602573-86-3 C₂₀H₂₆BrNO₃ 
• 375853-82-0 tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1(2H)-pyridinecarboxylate 
• 1382136-51-7 4-(5-bromo-2,3-dihydro-benzofuran-2-yl)-piperidine-1-carboxylic acid tert-butyl ester 
• 1602573-74-9 C₁₈H₂₅NO₃ 
• 54477-05-3 4-(benzofuran-2-yl)piperidine 
• 1602573-69-2 C₁₈H₂₃NO₄ 
• 271-89-6 1-benzofurane 

Downstream Products

• 1602575-13-2 C₂₅H₃₄N₂O₃ 
• 1346529-46-1 C₂₈H₄₀N₂O₅S 

Relevant academic research and scientific papers

Synthesis and structure-activity relationship of dihydrobenzofuran derivatives as novel human GPR119 agonists

Through appropriate medicinal chemistry design tactics and computer-assisted conformational modeling, the initial lead A was evolved into a series of dihydrobenzofuran derivatives 3 as potent GPR119 agonists. This Letter describes the optimization of general structure 3, including the substituent(s) on dihydrobenzofuran, the R1 attachment on right-hand piperidine nitrogen, and the left-hand piperidine/piperazine and its attachment R2. The efforts led to the identification of compounds 13c and 24 as potent human GPR119 modulators with favorable metabolic stability, ion channel activity, and PXR profiles.